The U.S. Food and Drug Administration granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi). The drug, a monoclonal antibody, binds to amyloid beta in the brain. An 18-month study published in the New England Journal of Medicine1 found Leqembi reduced markers of amyloid in early Alzheimer’s disease and led to “moderately less decline”… Read More »
From Dr. Joseph Mercola Since COVID-19 first entered the scene, exchange of ideas has basically been outlawed. By sharing my views and those from various experts throughout the pandemic on COVID treatments and the experimental COVID jabs, I became a main target of the White House, the political establishment and the global cabal. Propaganda and… Read More »
Martech specialist sets-up forward-thinking MNOs and Ecommerce brands for mobile marketing success Athens, London, Sao Paulo, 17 January 2023, – Upstream, the global mobile marketing technology specialist, is sharing its vision for the industry in 2023 as CMOs prioritise delivering personalized offers, exceptional customer experiences and targeted multichannel campaigns in the year ahead to support… Read More »
The annual growth forecast by the JOM Group foresees an increase of just 0.5 per cent for the 2023 advertising market in Germany. Hamburg, January 11, 2023. The German advertising market could have succeeded in returning to its pre-Covid-19 level as early as in 2022, and then pushed on to new heights in 2023. However,… Read More »
Much like air travel was fundamentally changed post-9/11 — justified by national security and the “war on terror” — the world is now profoundly different than its pre-COVID-19 state. Freedoms taken for granted in 2019 were abruptly taken away in 2020, again justified by national security and public health. But now, even with COVID-19 neutralized,… Read More »